Blocking the mitochondrial ADP/ATP carrier Ant2 does not simply “turn off” T cells. In preclinical work led by Prof. Michael Berger and teams at Hebrew University of Jerusalem, Philipps University of Marburg, and MD Anderson Cancer Center, Ant2 inhibition instead forces a metabolic switch that makes T cells more proliferative, durable, and effective against tumors in mice.
Why the simple “energy cut-off” story is misleading
Ant2 (an adenine nucleotide translocator) facilitates ADP/ATP exchange across the mitochondrial inner membrane; a headline that says “block Ant2, starve T cells” treats that single function as the whole story. The experiments show the opposite outcome: when Ant2 is removed from T cells, those cells shift away from reliance on oxidative phosphorylation and into an anabolic, activation-ready metabolic program rather than collapsing for lack of ATP.
This was demonstrated most directly in genetically engineered mice with T cell–specific Ant2 knockout. Those Ant2-deficient T cells exhibited increased mitochondrial biogenesis and higher NAD+ turnover — biochemical signs of a distinct metabolic state — and entered what the authors describe as a pre-activated state that accelerates proliferation and effector function in tumor models.
Exactly what the mouse experiments measured
In multiple tumor models the Ant2-deficient T cells proliferated faster and sustained anti-tumor activity longer than wild-type controls. The teams used both genetic knockout strategies (mouse lines engineered to lack Ant2 in T cells) and pharmacological ANT inhibitors applied to wild-type T cells; both approaches produced similar shifts in metabolism and improved tumor-killing in mice, strengthening the mechanistic link between Ant2 activity and T cell function.
Those findings are tied to concrete markers: enhanced mitochondrial mass, altered NAD+ handling, and transcriptional programs consistent with anabolism and early activation. In short, the cells become better adapted to the nutrient-deprived, hostile tumor microenvironment rather than being incapacitated by lack of mitochondrial ATP exchange.
What the evidence supports — and what it does not
The preclinical record supports three specific claims: (1) Ant2 inhibition rewires T cell metabolism away from oxidative phosphorylation toward anabolic processes; (2) that rewiring correlates with faster proliferation and more durable tumor suppression in mouse models; and (3) small-molecule ANT inhibitors can mimic, at least partially, the genetic knockout effects in experimental settings. What it does not prove, yet, is safety or efficacy in humans, optimal dosing regimens, or how ANT-targeting drugs will interact with current immunotherapies in clinical practice.
| Model/Condition | Observed metabolic change | Functional effect | Clinical unknowns |
|---|---|---|---|
| Ant2 T-cell knockout (mice) | ↑ mitochondrial biogenesis, ↑ NAD+ turnover, anabolic profile | ↑ proliferation, longer tumor control | Long-term safety, autoimmune risk, translation to humans |
| Pharmacologic ANT inhibitors (mouse/wild-type cells) | Similar metabolic shift reported | Improved tumor-killing capacity in models | Dosing window, off-target effects, replicability in human T cells |
| Human patients | Unknown | Unknown | Safety, efficacy, combination strategies with checkpoint blockade/chemotherapy |
How to think about translation: checkpoints, who benefits, and when to pause
Next practical checkpoints are clear. Researchers must show that pharmacological ANT inhibitors reproduce the metabolic and functional changes seen with genetic Ant2 knockout in human T cells ex vivo, establish a safe dosing range in vivo, and test combinations with existing immunotherapies. The authors and collaborating institutions — notably MD Anderson Cancer Center — emphasize these steps before any clinical trial is justified.
Who might benefit first? Patients whose tumors are resistant to current checkpoint inhibitors, or those with cold tumors where T cells struggle in a nutrient-poor microenvironment, are logical candidates for early translational studies. Stop signals would include evidence of systemic mitochondrial dysfunction, unexpected tissue toxicity, or disproportionate autoimmune activation in dose-escalation studies.
Short Q&A: common practical questions
Q: Does this mean ANT inhibitors will be cancer drugs soon?
Not immediately. The work is preclinical; key tests in human T cells and safety assessments are required before clinical trials.
Q: What biomarkers should researchers track?
Mitochondrial biogenesis, NAD+ turnover, proliferation markers, and early activation signatures in T cells — these were the direct readouts in the Berger-led studies.
Q: When would you stop a trial?
Clear signs of off-target mitochondrial impairment in non-immune tissues, severe autoimmune events, or inability to define a tolerable dosing window would be grounds to pause and reassess.